Cart
sales@molnova.com
PHI-101
CAS No. 2127107-15-5
PHI-101( —— )
Catalog No. M37298 CAS No. 2127107-15-5
PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 278 | Get Quote |
|
| 5MG | 436 | Get Quote |
|
| 10MG | 702 | Get Quote |
|
| 25MG | 1362 | Get Quote |
|
| 50MG | 2190 | Get Quote |
|
| 100MG | 3411 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePHI-101
-
NoteResearch use only, not for human use.
-
Brief DescriptionPHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
-
DescriptionPHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2127107-15-5
-
Formula Weight386.44
-
Molecular FormulaC19H19FN4O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (258.77 mM; Ultrasonic )
-
SMILESN(C(N)=O)C1=C(C(N[C@H]2CCCNC2)=O)SC(C#CC3=CC(F)=CC=C3)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.
molnova catalog
related products
-
Monalizumab
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
-
CCT241533
A potent and selective ATP-competitive inhibitor of CHK2 K5777:N5777with IC50 of 3 nM.
-
SAR-020106
SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC(50) of 13.3 nmol/L on the isolated human enzyme. This compound abrogates an etoposide-induced G(2) arrest with an IC(50) of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion.
